**Deep‑OMI: Real‑Time Optical Metabolic Imaging with Deep Learning for CAR‑T Cell Product Quality Control**

1. Introduction CAR‑T cell therapy has transformed the treatment of refractory hematologic malignancies, with FDA‑approved products achieving >80 % complete remission rates in relapsed B‑cell acute lymphoblastic leukemia (ALL). Despite clinical success, product variability remains a barrier to consistent outcomes. Metabolic phenotyping provides an uncommonly sensitive readout of mitochondrial fitness, activation status, and antigen‑specific cytotoxicity...